[Systematic review of economic evaluations of dabigatran for stroke prevention in atrial fibrilation]
Echeto García A, Bayón Yusta JC, Gardeazabal Romillo MJ, López de Argumedo González de Durana M, Acevedo Heranz P
Record ID 32018000615
Spanish
Original Title:
Revisión sistemática de la evidencia farmacoeconómica de dabigatrán para la prevención de ictus en pacientes con fibrilación auricular no valvular
Authors' objectives:
The objective of this report is to review of published economic evaluations of dabigatran etexylate for the stroke prevention in atrial fibrillation.
Authors' results and conclusions:
89 publication were found in reviewed databases. Only ten met the inclusion criteria and were critically assessed. The ten selected studies responded to most questions that are considered essential for quality (included in the checklist), so it was considered as good. However, it was found the existence of variability in dabigatran for indication considered in this cost-effectiveness study results .
Conclusions:
It highlighted the need to consider the external validity of the results of economic evaluations for decision-making related to the management of dabigatran in prevention of stroke. In systematic review, the validity was determined by the variability of costs, the long-term treatment of stroke and control of INR, and the characteristics of the population, the risk of stroke and / or bleeding and INR control.
Authors' methods:
Structured systematic review in reference database of scientific literature selection and critical appraisal of economic evaluations. The inclusion/exclusion criteria were defined. The search was conducted in scientific databases. Methodological quality was assessed by two investigators, using a checklist adapted from that proposed by Drummond and the Ministry of Health, Social Services and Equality from Spain.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.euskadi.eus/contenidos/informacion/2012_osteba_publicacion/es_def/adjuntos/eku_12_04_dabigatran_infor.pdf
English language abstract:
An English language summary is available
Publication Type:
Other
Country:
Spain
MeSH Terms
- Dabigatran
- Stroke
- Atrial Fibrillation
- Cost-Benefit Analysis
- Spain
Keywords
- Dabigatran
- Stroke
- Atrial Fibrillation
- Cost-Benefit Analysis
- Análisis Costo-Beneficio
- Fibrilación Atrial
- Accidente Cerebrovascular
- prevention and control
- prevención & control
Contact
Organisation Name:
Basque Office for Health Technology Assessment
Contact Address:
C/ Donostia – San Sebastián, 1 (Edificio Lakua II, 4ª planta) 01010 Vitoria - Gasteiz
Contact Name:
Lorea Galnares-Cordero
Contact Email:
lgalnares@bioef.eus
Copyright:
<p>Osteba (Basque Office for Health Technology Assessment) Health Department of the Basque Government</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.